Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

RecruitingOBSERVATIONAL
Enrollment

43

Participants

Timeline

Start Date

July 30, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2028

Conditions
Nasopharyngeal CarcinomaSintilimab
Interventions
DRUG

Sintilimab (PD-1 Antibody)

Patients will receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation plus Sintilimab, and then receive 11 cycles of Sintilimab after intensity-modulated radiotherapy (IMRT). All patients will receive IMRT. Sintilimab will begin on day 1 of induction chemotherapy and continue every 3 weeks for 17 cycles.

Trial Locations (1)

530021

RECRUITING

Guangxi Medical University Cancer Hospital, Nanning

All Listed Sponsors
lead

Cancer Hospital of Guangxi Medical University

OTHER